A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Launched by VANDA PHARMACEUTICALS · Jan 27, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how a medication called Tradipitant can help reduce nausea and vomiting in people who are using GLP-1R agonists, a type of treatment often used for obesity. The study will include healthy volunteers who are overweight or mildly to moderately obese. It is designed to compare the effects of Tradipitant with a placebo (a substance with no active medication) to see if it makes a difference in managing these symptoms.

To take part in this study, volunteers need to have a body mass index (BMI) between 25 and 40, which indicates they are overweight or mildly to moderately obese. They should not have any serious medical conditions or chronic diseases, such as diabetes. Participants will be monitored throughout the trial and can expect to receive either Tradipitant or a placebo. The trial is currently looking for volunteers and aims to help improve treatment options for nausea and vomiting related to obesity treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body Mass Index 25-40 kg/m\^2 inclusive
• • No serious medical problems or chronic diseases, specifically no type I or type II diabetes
• Exclusion Criteria:
• • Another disorder that contributes to gastrointestinal symptoms
• • History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
• • History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
• • Exposure to any investigational medication within the past 60 days